Alnylam Pharmaceuticals Inc (ALNY)vsCorMedix Inc (CRMD)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
CRMD
CorMedix Inc
$6.46
+0.62%
HEALTHCARE · Cap: $494.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 1091% more annual revenue ($3.71B vs $311.71M). CRMD leads profitability with a 52.3% profit margin vs 8.5%. CRMD trades at a lower P/E of 3.1x. CRMD earns a higher WallStSmart Score of 70/100 (B-).
ALNY
Hold49
out of 100
Grade: D+
CRMD
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+46.4%
Fair Value
$13.87
Current Price
$6.46
$7.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 67 in profit
Keeps 52 of every $100 in revenue as profit
Strong operational efficiency at 53.9%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
3.1% revenue growth
Smaller company, higher risk/reward
Earnings declined 28.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 52.3% and operating margin at 53.9%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : CRMD
The primary concerns for CRMD are Revenue Growth, Market Cap, EPS Growth.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while CRMD is a value play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.42 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (70/100 vs 49/100), backed by strong 52.3% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?